Market Closed -
Hong Kong S.E.
04:08:07 2024-05-09 am EDT
|
5-day change
|
1st Jan Change
|
13.16
HKD
|
+6.65%
|
|
+1.54%
|
+38.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,593
|
6,540
|
4,374
|
5,052
|
7,590
|
10,699
|
-
|
-
|
Enterprise Value (EV)
1 |
17,849
|
5,031
|
6,436
|
7,873
|
7,590
|
10,699
|
10,699
|
10,699
|
P/E ratio
|
9.86
x
|
14
x
|
-7.42
x
|
63.8
x
|
3.82
x
|
-
|
-
|
-
|
Yield
|
3.29%
|
1.35%
|
-
|
-
|
-
|
8.22%
|
8.06%
|
8.72%
|
Capitalization / Revenue
|
2.83
x
|
2.79
x
|
4.79
x
|
1.35
x
|
1.21
x
|
1.62
x
|
1.6
x
|
1.59
x
|
EV / Revenue
|
2.83
x
|
2.79
x
|
4.79
x
|
1.35
x
|
1.21
x
|
1.62
x
|
1.6
x
|
1.59
x
|
EV / EBITDA
|
6.87
x
|
4.75
x
|
-25.2
x
|
7.23
x
|
2.76
x
|
4.64
x
|
4.44
x
|
4.53
x
|
EV / FCF
|
14,442,826
x
|
21,418,312
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5.22
x
|
1.34
x
|
0.75
x
|
0.86
x
|
-
|
1.23
x
|
1.09
x
|
0.99
x
|
Nbr of stocks (in thousands)
|
889,785
|
879,968
|
879,968
|
879,968
|
879,968
|
879,968
|
-
|
-
|
Reference price
2 |
19.77
|
7.432
|
4.970
|
5.741
|
8.626
|
12.16
|
12.16
|
12.16
|
Announcement Date
|
3/27/20
|
3/19/21
|
3/21/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,224
|
2,348
|
913.8
|
3,745
|
6,295
|
6,596
|
6,706
|
6,745
|
EBITDA
1 |
2,560
|
1,377
|
-173.5
|
698.4
|
2,745
|
2,304
|
2,412
|
2,361
|
EBIT
1 |
2,474
|
1,255
|
-423.4
|
321.1
|
2,354
|
2,243
|
2,347
|
2,293
|
Operating Margin
|
39.74%
|
53.43%
|
-46.33%
|
8.57%
|
37.4%
|
34%
|
35%
|
34%
|
Earnings before Tax (EBT)
|
2,269
|
1,010
|
-667.2
|
-
|
2,127
|
-
|
-
|
-
|
Net income
|
1,919
|
839.5
|
-587.6
|
-
|
1,993
|
-
|
-
|
-
|
Net margin
|
30.83%
|
35.75%
|
-64.31%
|
-
|
31.66%
|
-
|
-
|
-
|
EPS
|
2.005
|
0.5300
|
-0.6700
|
0.0900
|
2.260
|
-
|
-
|
-
|
Free Cash Flow
|
1,218
|
305.3
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
19.57%
|
13%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
47.59%
|
22.17%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
63.49%
|
36.37%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.6500
|
0.1000
|
-
|
-
|
-
|
1.000
|
0.9800
|
1.060
|
Announcement Date
|
3/27/20
|
3/19/21
|
3/21/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 S1
|
2022 S2
|
---|
Net sales
1 |
-
|
2,452
|
EBITDA
|
-
|
-
|
EBIT
1 |
-
|
220.5
|
Operating Margin
|
-
|
8.99%
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-32.8
|
-
|
Net margin
|
-
|
-
|
EPS
2 |
-0.0400
|
0.1300
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
8/26/22
|
3/24/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
256
|
-
|
2,062
|
2,822
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
1,509
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.1001
x
|
-
|
-11.89
x
|
4.04
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
1,218
|
305
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
48.9%
|
18.1%
|
-11%
|
1.31%
|
-
|
21.7%
|
20.8%
|
18.7%
|
ROA (Net income/ Total Assets)
|
26.5%
|
8.62%
|
-5.85%
|
-
|
-
|
-
|
-
|
-
|
Assets
|
7,237
|
9,737
|
10,051
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
1 |
3.790
|
5.550
|
6.600
|
6.690
|
-
|
9.890
|
11.10
|
12.30
|
Cash Flow per Share
|
1.540
|
1.180
|
-0.7500
|
-
|
-
|
-
|
-
|
-
|
Capex
|
576
|
994
|
356
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
9.26%
|
42.34%
|
38.99%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/19/21
|
3/21/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
12.16
CNY Average target price
12.94
CNY Spread / Average Target +6.43% Consensus |
1st Jan change
|
Capi.
|
---|
| +38.67% | 1.39B | | +32.36% | 698B | | +26.51% | 568B | | -4.40% | 358B | | +19.46% | 328B | | +3.50% | 283B | | +16.34% | 238B | | +6.68% | 203B | | -9.08% | 198B | | +8.62% | 165B |
Other Pharmaceuticals
|